Cartesian Therapeutics | ClinicalTrials HQ

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis	Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome	Active, not recruiting	Phase 3	2026-09-01		NCT06799247
Descartes-08 in Autoantibody Myositis	antisynthetase syndrome, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease	Recruiting	Phase 2	2026-08-17		NCT07391605
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)	Myasthenia Gravis, Generalized, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome	Active, not recruiting	Phase 2	2026-08-14		NCT04146051
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders	Skin and Connective Tissue Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune disease, cardiovascular disorder, connective tissue disorder, dermatomyositis, immune system disorder, juvenile myasthenia gravis, muscle tissue disorder, musculoskeletal system disorder, myositis disease, necrotizing vasculitis, nervous system disorder, neuromuscular disease, polymyositis, skin disorder, skin vascular disease, vascular disorder, vasculitis	Recruiting	Phase 1 / Phase 2	2026-07-27		NCT07089121
Descartes-08 for Patients With Systemic Lupus Erythematosus	Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus	Active, not recruiting	Phase 2	2026-03-27		NCT06038474